Search

Your search keyword '"Fang J"' showing total 440 results

Search Constraints

Start Over You searched for: Author "Fang J" Remove constraint Author: "Fang J" Publisher elsevier bv Remove constraint Publisher: elsevier bv
440 results on '"Fang J"'

Search Results

1. A systematic approach for the adequacy analysis of a set of experimental databases: Application in the framework of the ATRIUM activity

2. Diabetes Therapy with Novel Agents After Heart Transplant: A Multi-Institutional Analysis

3. Relationship of Systemic Vascular Resistance with Mortality in Cardiogenic Shock

4. Search for a massless particle beyond the Standard Model in the Σ+ → p + invisible decay

6. MA14.05 Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib

7. OA21.03 A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

8. Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension

15. Determination of spin and parity of D(s)⁎ mesons

16. Search for the semi-leptonic decays Λc+→Λπ+π−e+νe and Λc+→pKS0π−e+νe

22. (488) Impaired Liver Function is Associated with Hypotension and Elevated Right Atrial Pressure but Not Depressed Cardiac Index in Chronic Heart Failure

23. Search for invisible decays of a dark photon using e+e− annihilation data at BESIII

24. OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

25. Search for an axion-like particle in radiative J/ψ decays

27. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

28. 305MO SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

30. LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study

31. Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

32. EP08.01-042 NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

33. EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

35. LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study

36. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

37. OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

38. EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC

39. OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study

40. 987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study

41. 981P A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation

42. 1034P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EFGR-TKIs

44. Measurement of the e+e−→Σ0Σ¯0 cross sections at center-of-mass energies from 2.3864 to 3.0200 GeV

46. Shear-induced alignment in 3D-printed nitrile rubber-reinforced glass fiber composites

47. 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

48. 8MO The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer

49. 2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC

Catalog

Books, media, physical & digital resources